Yes, some of the current vaccines might hold promise for short term partial immunity. The below is from another company I follow that is taking a different approach:
'The Ii-Key-SARS-CoV-2 peptide epitopes, which contain target amino acid sequences from the
virus, will be screened against blood samples collected from COVID-19 convalescent (recovered)
patients to select those Ii-Key peptides that activate the immune system to fight the coronavirus
infection. The blood screening program, which is scheduled to begin next week, incorporates T
Cell Assays, antibody screening and isolation, virus neutralization tests(PRNT – Plaque Reduction
Neutralization Test), and a novel in-vitro “cytokine storm” cellular assay. Through this proprietary
method, Generex can identify the Ii-Key-SARS-CoV-2 peptides vaccines most likely to stimulate
the appropriate T-Cell (CD4 and CD8) responses and modulate the correct immune system
responses to minimize potential for dysregulated cytokine-related inflammation, stimulate a
neutralizing antibody response, with the goal of providing a broad-spectrum coverage for the
vast majority of people. This strategy leverages Ii-Key technology to develop a “Complete
Vaccine” that has the potential to induce the likelihood of protective immunity with long-lasting
immunologic memory against SARS-COV-2 in a highly specific manner to ensure safety.
Generex CEO, Joseph Moscato said, “Since we filed our application with BARDA for the
development of a COVID-19 vaccine eleven weeks ago, we have pushed forward with our Ii-KeySARS-CoV-2 vaccine development program, making significant strides. We have manufactured
the Ii-Key-SARS-CoV-2 peptides that have been selected based on computational analysis of the
viral sequence. We have secured blood samples from convalescent COVID-19 patients and
isolated the peripheral blood monocytes cells (PBMCs) that will be used by our immunology
laboratories for testing of the Ii-Key peptides in our COVID-19 blood screening program. Working
with our integrated team of internal and external professionals, we have finalized our protocol,
which is comprehensive and highly focused on the safety of human subjects who enroll in our
trials. Additionally, the protocol provides for a thorough immunology analysis to determine the
exact immunological responses generated by Ii-Key vaccination. With this Pre-IND submission,
we have highlighted the potential for our Ii-Key-SARS-CoV-2 to provide a “Complete Vaccine”
that not only provides a short-term antibody response, but also a long-lasting neutralizing
antibody response and a CD4+ Th1 T-cell response to ensure immune system memory and longterm immunity from COVID-19. We look forward to working with the FDA to define a clear path
to commercialization for our Ii-Key-SARS-CoV-2 vaccine and we will keep our investors informed
as the development program progresses.”
While I hope that company is successful, we still need Leronlimab and any other treatment approach benefiting patients.
I cannot wait to hear what is said at the CV task force press conference and get Dr Yo's take on Dr Drew's show this afternoon.
PSA: Don't forget to vote on the authorized share increase.
'The Ii-Key-SARS-CoV-2 peptide epitopes, which contain target amino acid sequences from the
virus, will be screened against blood samples collected from COVID-19 convalescent (recovered)
patients to select those Ii-Key peptides that activate the immune system to fight the coronavirus
infection. The blood screening program, which is scheduled to begin next week, incorporates T
Cell Assays, antibody screening and isolation, virus neutralization tests(PRNT – Plaque Reduction
Neutralization Test), and a novel in-vitro “cytokine storm” cellular assay. Through this proprietary
method, Generex can identify the Ii-Key-SARS-CoV-2 peptides vaccines most likely to stimulate
the appropriate T-Cell (CD4 and CD8) responses and modulate the correct immune system
responses to minimize potential for dysregulated cytokine-related inflammation, stimulate a
neutralizing antibody response, with the goal of providing a broad-spectrum coverage for the
vast majority of people. This strategy leverages Ii-Key technology to develop a “Complete
Vaccine” that has the potential to induce the likelihood of protective immunity with long-lasting
immunologic memory against SARS-COV-2 in a highly specific manner to ensure safety.
Generex CEO, Joseph Moscato said, “Since we filed our application with BARDA for the
development of a COVID-19 vaccine eleven weeks ago, we have pushed forward with our Ii-KeySARS-CoV-2 vaccine development program, making significant strides. We have manufactured
the Ii-Key-SARS-CoV-2 peptides that have been selected based on computational analysis of the
viral sequence. We have secured blood samples from convalescent COVID-19 patients and
isolated the peripheral blood monocytes cells (PBMCs) that will be used by our immunology
laboratories for testing of the Ii-Key peptides in our COVID-19 blood screening program. Working
with our integrated team of internal and external professionals, we have finalized our protocol,
which is comprehensive and highly focused on the safety of human subjects who enroll in our
trials. Additionally, the protocol provides for a thorough immunology analysis to determine the
exact immunological responses generated by Ii-Key vaccination. With this Pre-IND submission,
we have highlighted the potential for our Ii-Key-SARS-CoV-2 to provide a “Complete Vaccine”
that not only provides a short-term antibody response, but also a long-lasting neutralizing
antibody response and a CD4+ Th1 T-cell response to ensure immune system memory and longterm immunity from COVID-19. We look forward to working with the FDA to define a clear path
to commercialization for our Ii-Key-SARS-CoV-2 vaccine and we will keep our investors informed
as the development program progresses.”
While I hope that company is successful, we still need Leronlimab and any other treatment approach benefiting patients.
I cannot wait to hear what is said at the CV task force press conference and get Dr Yo's take on Dr Drew's show this afternoon.
PSA: Don't forget to vote on the authorized share increase.
5
